One prospective treatment option for vocal fold scarring is regeneration with an engineered scaffold containing induced pluripotent stem cells (iPS). In the present study, we investigated the feasibility of utilizing an injectable hyaluronic acid (HA) scaffold encapsulated with human-iPS cell (hiPS) for regeneration of vocal folds.
Methods:
Thirty athymic nude rats underwent unilateral vocal fold injury. Contralateral vocal folds served as uninjured controls. Hyaluronic acid hydrogel scaffold, HA hydrogel scaffold containing hiPS, and HA hydrogel scaffold containing hiPS with epidermal growth factor (EGF) were injected in both vocal folds immediately after surgery. One and 2 weeks after injection, larynges were excised for histology, immunohistochemistry, and fluorescence in situ hybridization (FISH).
Results:
Presence of HA hydrogel was confirmed in vocal folds 1 and 2 weeks post injection. The FISH analysis confirmed the presence and viability of hiPS in the injected vocal folds. Histological results demonstrated that vocal folds injected with HA hydrogel scaffold containing EGF demonstrated less fibrosis than those with HA hydrogel only.
Conclusions:
Human-iPS survived in injured rat vocal folds. The HA hydrogel with hiPS and EGF ameliorated the fibrotic response. Additional work is necessary to optimize hiPS differentiation and further confirm the safety of hiPS for clinical applications.
HansenJKThibeaultSL.Current understanding and review of the literature: vocal fold scarring. J Voice. 2006;20:110-120.
2.
MortensenM.Laryngeal steroid injection for vocal fold scar. Curr Opin Otolaryngol Head Neck Surg. 2010;18:487-491.
3.
BrandenburgJHKirkhamWKoschkeeD.Vocal cord augmentation with autogenous fat. Laryngoscope. 1992;102:495-500.
4.
RihkanenH.Vocal fold augmentation by injection of autologous fascia. Laryngoscope. 1998;108:51-54.
5.
DaileySHGundersonMChanRTorrealbaJKimuraMWelhamNV.Local vascularized flaps for augmentation of Reinke’s space. Laryngoscope. 2011;121(suppl 3):S37-S60.
6.
MasonCDunnillP.A brief definition of regenerative medicine. Regen Med. 2008;3:1-5.
7.
JohnsonBQFoxRChenXThibeaultS.Tissue regeneration of the vocal fold using bone marrow mesenchymal stem cells and synthetic extracellular matrix injections in rats. Laryngoscope. 2010;120:537-545.
8.
OishiKNoguchiHYukawaHHayashiS.Differential ability of somatic stem cells. Cell Transplant. 2009;18:581-589.
9.
ThomsonJAItskovitz-EldorJShapiroSS. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-1147.
10.
TakahashiKYamanakaS.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
11.
SenjuSHarutaMMatsunagaY. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells. 2009;27:1021-1031.
12.
TashiroKInamuraMKawabataK. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. Stem Cells. 2009;27:1802-1811.
13.
ImaizumiMNomotoYSuginoT. Potential of induced pluripotent stem cells for the regeneration of the tracheal wall. Ann Otol Rhinol Laryngol. 2010;119:697-703.
14.
ImaizumiMNomotoYSatoY. Evaluation of the use of induced pluripotent stem cells (iPSCs) for the regeneration of tracheal cartilage iPSCs for regeneration of tracheal cartilage. Cell Transplant. 2013;22(2):341-353.
15.
ImaizumiMSatoYYangDTThibeaultSL.In vitro epithelial differentiation of human induced pluripotent stem cells for vocal fold tissue engineering. Ann Otol Rhinol Laryngol. 2013;122:737-747.
16.
ThibeaultSLRousseauBWelhamNVHiranoSBlessDM.Hyaluronan levels in acute vocal fold scar. Laryngoscope. 2004;114:760-764.
17.
DufloSThibeaultSLLiWShuXZPrestwichG.Effect of a synthetic extracellular matrix on vocal fold lamina propria gene expression in early wound healing. Tissue Eng. 2006;12:3201-3207.
18.
CatonTThibeaultSLKlemukSSmithME.Viscoelasticity of hyaluronan and nonhyaluronan based vocal fold injectables: implications for mucosal versus muscle use. Laryngoscope. 2007;117:516-521.
19.
ThibeaultSLDufloS.Inflammatory cytokine responses to synthetic extracellular matrix injection to the vocal fold lamina propria. Ann Otol Rhinol Laryngol. 2008;117:221-226.
20.
YuJVodyanikMASmuga-OttoK. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
21.
ShuXZLiuYPalumboFPrestwichGD.Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials. 2003;24:3825-3834.
22.
ShuXZGhoshKLiuY. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A. 2004;68:365-375.
CaiSLiuYZheng ShuXPrestwichGD.Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials. 2005;26:6054-6067.
25.
HougenHP.The athymic nude rat. Immunobiological characteristics with special reference to establishment of non-antigen-specific T-cell reactivity and induction of antigen-specific immunity. APMIS Supplementum. 1991;21:1-39.
26.
SeoBFLeeJYJungS-N.Models of abnormal scarring. Biomed Res Int. 2013;2013:8.
27.
KanemaruSNakamuraTOmoriK. Regeneration of the vocal fold using autologous mesenchymal stem cells. Ann Otol Rhinol Laryngol. 2003;112:915-920.
28.
CedervallJAhrlund-RichterLSvenssonB. Injection of embryonic stem cells into scarred rabbit vocal folds enhances healing and improves viscoelasticity: short-term results. Laryngoscope. 2007;117:2075-2081.
29.
MiuraKOkadaYAoiT. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009;27:743-745.
30.
ImaizumiMNomotoYSuginoTOtsukiKOmoriK.Implantation site-dependent differences for tracheal regeneration with induced pluripotent stem cells (iPS cells). Acta Otolaryngol. 2013;133:405-411.
31.
NishimuraKNakagawaTSakamotoTItoJ.Fates of murine pluripotent stem cell-derived neural progenitors following transplantation into mouse cochleae. Cell Transplant. 2012;21:763-771.
32.
LiNYLeeBJThibeaultSL.Temporal and spatial expression of high-mobility group box 1 in surgically injured rat vocal folds. Laryngoscope. 2012;122:364-369.
33.
ImaizumiMThibeaultSLLeydonC.Classification for animal vocal fold surgery: resection margins impact histological outcomes of vocal fold injury. Laryngoscope. 2014;124:E437-E444.
34.
CoppoolseJMVan KootenTGHerisHK. An in vivo study of composite microgels based on hyaluronic acid and gelatin for the reconstruction of surgically injured rat vocal folds. J Speech Lang Hear Res. 2014;57:S658-S673.
35.
TateyaTTateyaISohnJHBlessDM.Histologic characterization of rat vocal fold scarring. Ann Otol Rhinol Laryngol. 2005;114:183-191.
36.
OgawaTAkazawaTTabataY.In vitro proliferation and chondrogenic differentiation of rat bone marrow stem cells cultured with gelatin hydrogel microspheres for TGF-beta1 release. J Biomater Sci Polym Ed. 2010;21:609-621.
37.
ChenCHShyuVBChenJPLeeMY.Selective laser sintered poly-epsilon-caprolactone scaffold hybridized with collagen hydrogel for cartilage tissue engineering. Biofabrication. 2014;6:015004.
38.
ThibeaultSLKlemukSAChenXQuinchia JohnsonBH.In vivo engineering of the vocal fold ECM with injectable HA hydrogels-late effects on tissue repair and biomechanics in a rabbit model. J Voice. 2011;25:249-253.
39.
DufloSThibeaultSLLiWShuXZPrestwichGD.Vocal fold tissue repair in vivo using a synthetic extracellular matrix. Tissue Eng. 2006;12:2171-2180.
40.
SibiliaMWagnerEF.Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 1995;269:234-238.
41.
MiettinenPJBergerJEMenesesJ. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 1995;376:337-341.
42.
KrysanKLeeJMDohadwalaM. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008;3:107-110.
43.
TamamaKKawasakiHWellsA.Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol. 2010;2010:10.
44.
XiaGMartinAEBesnerGE.Heparin-binding EGF-like growth factor downregulates expression of adhesion molecules and infiltration of inflammatory cells after intestinal ischemia/reperfusion injury. J Pediatr Surg. 2003;38:434-439.
45.
PastoreSMasciaFMarianiVGirolomoniG.The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol. 2008;128:1365-1374.
46.
LuettekeNCQiuTHPeifferRLOliverPSmithiesOLeeDC.TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell. 1993;73:263-278.
47.
SinglaSSinglaSKumarASinglaM.Role of epidermal growth factor in healing of diabetic foot ulcers. Indian J Surg. 2012;74:451-455.
48.
DoerlerMEmingSDissemondJ. A novel epidermal growth factor-containing wound dressing for the treatment of hard-to-heal venous leg ulcers. Adv Skin Wound Care. 2014;27:456-460.
49.
MasumotoHIkunoTTakedaM. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014;4:6716.
50.
SongGLiXShenY. Transplantation of iPSc restores cardiac function by promoting angiogenesis and ameliorating cardiac remodeling in a post-infarcted swine model. Cell Biochem Biophys. 2015;71(3):1463-1473.
